Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07132645 · ClinicalTrials.gov registry record · Early Phase 1
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
A Early Phase 1 study of Neuroendocrine Tumor, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07132645 is a Early Phase 1 study of Neuroendocrine Tumor that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 30 participants, below the 139-participant average among 6 other Neuroendocrine Tumor trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07132645, a Early Phase 1 study of Neuroendocrine Tumor, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial determines where and to what degree the tracer \[68Ga\] Ga-FAPI-04 accumulates in normal and cancer tissues in patients with high grade neuroendocrine cancer. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research \[68Ga\] Ga-FAPI-04. Because some cancers take up \[68Ga\] Ga-FAPI-04, it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- DRUG Gallium Ga 68-DOTA-FAPI-04
- PROCEDURE Positron Emission Tomography
Study Locations (1)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-16 |
| Est. Completion | 2027-09-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07132645
The ClinicalTrials.gov registry entry for NCT07132645 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 6 other Neuroendocrine Tumor trials with a reported enrollment target (78% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroendocrine Tumor appearing as the primary indexed condition, and to 3 interventions - of which Computed Tomography is the first listed.
NCT07132645 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07132645 about?
NCT07132645 is a clinical study titled "An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer". This early phase I trial determines where and to what degree the tracer \[68Ga\] Ga-FAPI-04 accumulates in normal and cancer tissues in patients with high grade neuroendocrine cancer. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amount...
What is the current status of trial NCT07132645?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-09-16. Estimated completion is 2027-09-01.
What conditions does trial NCT07132645 study?
This clinical trial studies the following conditions: Neuroendocrine Tumor.
What interventions are being tested in trial NCT07132645?
The interventions under investigation include: Computed Tomography (PROCEDURE), Gallium Ga 68-DOTA-FAPI-04 (DRUG), Positron Emission Tomography (PROCEDURE).
Who is sponsoring clinical trial NCT07132645?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07132645 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases
RECRUITING · NA
-
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
ACTIVE NOT RECRUITING · Phase 3
-
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
COMPLETED · Phase 2
-
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
COMPLETED · Phase 2
-
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
COMPLETED · Phase 2
-
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.